New hope for myelofibrosis: drug combo targets tough cases
NCT ID NCT06909136
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (WJ01024) combined with an existing drug (ruxolitinib) in 33 adults with intermediate- or high-risk myelofibrosis whose spleen is enlarged and who didn't respond well to or couldn't tolerate previous JAK inhibitor treatments. The goal is to see if the combination is safe and can shrink the spleen and reduce symptoms. The trial has two phases: first finding the right dose, then testing how well it works.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- WJ01024 tablets combined with ruxolitinib tablets
- What this could lead to
- If successful, this combination could offer a new treatment option for people with myelofibrosis who haven't responded well to or can't tolerate current JAK inhibitor therapy.
- What could go wrong
- This is an early-phase trial with only 33 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink the spleen or improve symptoms significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
33 people
The number who actually took part.
- Started
-
Jul 2025
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects voluntarily participate in the study after receiving full informed consent and sign informed consent; * Age ≥18 years old, gender unlimited; * Patients diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition), or with ET secondary myelofibrosis (PET-MF) or PV secondary myelofibrosis (PPV-MF) according to International Working Group on Myelofibrosis Research and Treatment (IWG-MRT) criteria; They could be included regardless of JAK2 mutation； * Participants with international prognostic scoring system (DIPSS) risk category of intermediate-1, or intermediate-2, or high-risk； * ECOG score 0\~2; * No stem cell transplantation plan in the near future; * Spleen enlargement:palpable splenomegaly(≥5cm below left costal margin)or radiologically confirmed spleen volume ≥450 cm\^3 using MRI/CT; * Patients with intolerance or a suboptimal response to prior JAK inhibitor therapy； * Sufficient hematology and organ function； Exclusion Criteria: * More than 10% blasts in peripheral blood or bone marrow； * Previous treatment with XPO1 inhibitors； * Unable to cooperate with or unable to perform MRI or CT scans as deemed necessary by sponsor and investigator； * Treatment with a powerful CYP3A inhibitor or inducer within 14 days prior to initial administration；
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Intermediate- and high-risk myelofibrosis (MF) patients with splenomegaly are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
Zhengzhou, Zhengzhou, 450000, China